These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 38547425)
41. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Zinzani PL; Vose JM; Czuczman MS; Reeder CB; Haioun C; Polikoff J; Tilly H; Zhang L; Prandi K; Li J; Witzig TE Ann Oncol; 2013 Nov; 24(11):2892-7. PubMed ID: 24030098 [TBL] [Abstract][Full Text] [Related]
42. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. Foss FM; Parker T Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091 [TBL] [Abstract][Full Text] [Related]
43. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842 [TBL] [Abstract][Full Text] [Related]
44. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412 [TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of blinatumomab: a real world data. Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826 [TBL] [Abstract][Full Text] [Related]
46. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690 [TBL] [Abstract][Full Text] [Related]
47. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635 [TBL] [Abstract][Full Text] [Related]
48. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Doraiswamy A; Shah MR; Bannerji R Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641 [TBL] [Abstract][Full Text] [Related]
49. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Laetsch TW; Maude SL; Rives S; Hiramatsu H; Bittencourt H; Bader P; Baruchel A; Boyer M; De Moerloose B; Qayed M; Buechner J; Pulsipher MA; Myers GD; Stefanski HE; Martin PL; Nemecek E; Peters C; Yanik G; Khaw SL; Davis KL; Krueger J; Balduzzi A; Boissel N; Tiwari R; O'Donovan D; Grupp SA J Clin Oncol; 2023 Mar; 41(9):1664-1669. PubMed ID: 36399695 [No Abstract] [Full Text] [Related]